Edition:
India

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

4.78USD
9:20pm IST
Change (% chg)

$-0.06 (-1.24%)
Prev Close
$4.84
Open
$4.84
Day's High
$4.88
Day's Low
$4.78
Volume
26,456
Avg. Vol
488,906
52-wk High
$6.55
52-wk Low
$1.17

Select another date:

Fri, Nov 17 2017

BRIEF-‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6

* ‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​ Source text: [http://bit.ly/2A4glhH] Further company coverage:

BRIEF-Endocyte Q3 loss per share $0.55

* Q3 loss per share $0.55 Source text for Eikon: Further company coverage:

BRIEF-Endocyte Inc files for mixed shelf of upto $150 million

* Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​ Source text: (http://bit.ly/2i7ELz2) Further company coverage:

BRIEF-Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc

* Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing Source text : (http://bit.ly/2gyKxWH) Further company coverage:

BRIEF-Endocyte announces worldwide license of its radioligand therapy

* Endocyte announces exclusive worldwide license of phase 3 ready PSMA-targeted radioligand therapy for development in prostate cancer

BRIEF-Endocyte says ABX GmbH eligible for milestones of up to $160 mln under license agreement

* Endocyte Inc - ‍ABX is eligible for regulatory and commercial milestones of up to $160 million, and tiered royalties beginning in mid-teens​

BRIEF-Endocyte Q2 loss per share $0.28

* Endocyte reports second quarter financial results and provides clinical and pipeline update

BRIEF-Endocyte form 4 discloses CEO's 44,285 stock options fully vested on May 31, immediately exercisable

* Endocyte Inc form 4 discloses that CEO Michael Sherman's 44,285 stock options (right to buy) fully vested on may 31 and immediately exercisable - sec filing Source text (http://bit.ly/2rytsCJ) Further company coverage:

BRIEF-Endocyte announces clinical updates for EC1456 and EC1169

* Endocyte Inc - continuing EC1169 program in taxane-exposed patients, but ending clinical development of EC1456 and of EC1169 in taxane-naïve patients

Select another date: